Follow-Up of Patients with Multidrug Resistant Tuberculosis Four Years after Standardized First-Line Drug Treatment
Open Access
- 24 May 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (5), e10799
- https://doi.org/10.1371/journal.pone.0010799
Abstract
In 2004, an anti-tuberculosis (TB) drug resistance survey in Heilongjiang province, China, enrolled 1574 (79%) new and 421 (21%) retreatment patients. Multi-drug resistant (MDR) TB was detected in 7.2% of new and 30.4% of retreatment patients. All received treatment with standardized first-line drug (FLD) regimens. We report treatment outcomes of the 2004 cohort, and long-term outcomes as assessed in the second half of 2008. The reported cure rate for MDR-TB patients was 83% (94/113) among new and 66% (85/128) among retreatment patients (P<0.001). Ten of the 241 MDR-TB patients died during treatment. Of the remaining 231, 129 (56%) could be traced in 2008. The overall recurrence rates among new and retreatment cases were 46% and 66%, respectively (P = 0.03). The overall death rates among new and retreatment cases were 25% and 46%, respectively (P = 0.02). Forty percent of the traced new cases and 24% of the retreatment cases were alive and without recurrent TB (P = 0.01). Of the 16 patients who failed or defaulted from treatment in 2004, only two patients were not re-diagnosed with TB by 2008. Of the 111 (86%) patients with an initial successful treatment outcome 63 (57%) had developed recurrent TB, 40 (36%) had died, 27 (24%) of them died of TB. The follow-up period of four years precluded follow-up of all patients. In a highly conservative sensitivity analysis in which we assumed that all non-included patients were alive and did not have recurrent TB, the recurrence and death rate were 33% and 21%. Documentation of cure based on conventional smear microscopy was a poor predictor of long term outcomes. MDR-TB patients in Heilongjiang province in China had high recurrence and death rates four years after treatment with standardized FLD regimens, reinforcing the need for early diagnosis and treatment of MDR-TB, including assessment of treatment outcomes with more sensitive laboratory methods.Keywords
This publication has 17 references indexed in Scilit:
- Ministerial meeting agrees plan for tuberculosis control.The Lancet, 2009
- Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug ResistancePLoS Medicine, 2006
- [Impact of anti-tuberculosis drug resistance on treatment outcome of pulmonary tuberculosis patients receiving directly observed treatment strategy in Henan Province, China].2006
- Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up studyEuropean Respiratory Journal, 2006
- Tuberculosis drug resistance and treatment outcomes under DOTS settings in large cities in the Philippines.2006
- Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam.2006
- Does one size fit all? Drug resistance and standard treatments: results of six tuberculosis programmes in former Soviet countries.2005
- A Nested Case–Control Study on Treatment-related Risk Factors for Early Relapse of TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Worldwide Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2002
- Standard Short-Course Chemotherapy for Drug-Resistant TuberculosisJAMA, 2000